Mark Bazett serves as the Senior Director of Preclinical Development at Bold Therapeutics Inc., where he plays a pivotal role in advancing innovative therapeutics through the complex landscape of drug development. With a robust background in immunology and a specialization in oncology and inflammatory diseases,...
Mark Bazett serves as the Senior Director of Preclinical Development at Bold Therapeutics Inc., where he plays a pivotal role in advancing innovative therapeutics through the complex landscape of drug development. With a robust background in immunology and a specialization in oncology and inflammatory diseases, Mark leads a dynamic preclinical research team focused on the nonclinical development of BOLD-100, a groundbreaking anticancer and antiviral therapeutic. His expertise in cell biology and flow cytometry, combined with his adeptness in managing diverse research initiatives, positions him as a key driver of scientific innovation within the organization.
In his current role, Mark is responsible for overseeing the strategic direction of preclinical studies, ensuring that they align with the overarching goals of Bold Therapeutics. He actively collaborates with an extensive network of experts, fostering academic partnerships that enhance the scientific rigor of ongoing projects. His leadership extends to acquiring and deploying non-dilutive funding, which is crucial for advancing BOLD-100 through the preclinical pipeline. Mark’s deep understanding of respiratory mechanics and inflammatory bowel disease (IBD) research further enriches his contributions, allowing him to integrate cutting-edge scientific insights into practical applications.
Mark's adaptability and experience in research and development (R&D) enable him to navigate the challenges of bringing unique therapeutics to clinical investigations. His commitment to excellence and innovation not only drives the success of Bold Therapeutics but also contributes to the broader field of life sciences, ultimately aiming to improve patient outcomes in oncology and beyond.
